Optimizing Biomarker Testing in Your Practice: Leveraging In-House Testing Strategies - Episode 10

Decentralization of Biomarker Testing: Expanding Access to Targeted Therapies and Clinical Trials in Underserved Populations

February 10, 2025

Panelists discuss how decentralizing biomarker testing improves access to targeted therapies and clinical trials for underserved populations by reducing geographic and systemic barriers, fostering equity in cutting-edge health care.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Key Considerations When Ordering Biomarker Testing

EP. 2: The Importance of Broad Biomarker Testing: Uncovering Actionable Targets Across Tumor Types

EP. 3: When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis

EP. 4: Centralized vs Decentralized Biomarker Testing: Workflow, Control, and Collaboration Insights

EP. 5: In-House Comprehensive Genomic Profiling: Expert Insight Into Balancing Benefits and Challenges

EP. 6: Implementing In-House Biomarker Testing: Rationale and Key Considerations

EP. 7: Optimizing In-House Testing: Enhancing Efficiency for Timely Results and Treatment Decisions

EP. 8: Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing

EP. 9: Impact of In-House Testing on Improved Cancer Care: Timely Decisions and Enhanced Treatment Accuracy

Now Viewing

EP. 10: Decentralization of Biomarker Testing: Expanding Access to Targeted Therapies and Clinical Trials in Underserved Populations

EP. 11: Mitigating Socioeconomic Disparities Through Decentralized Testing: Overcoming Barriers to Access and Equity

EP. 12: Key Takeaways and Future Perspectives for In-House Biomarker Testing

Video series above is prompted by the following:

What are your thoughts on how decentralization of biomarker testing might address access to targeted therapies and clinical trials in underserved populations?
Explore how testing decentralization can bridge gaps in access to cutting-edge treatments and clinical trials for marginalized or geographically distant populations.